(4,4-Difluoropiperidin-1-yl)-[6-(3-methylsulfonylanilino)-4-azatricyclo[6.2.1.02,7]undeca-2(7),3,5-trien-3-yl]methanone | 1357184-25-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 英文名称: (4,4-Difluoropiperidin-1-yl)-[6-(3-methylsulfonylanilino)-4-azatricyclo[6.2.1.02,7]undeca-2(7),3,5-trien-3-yl]methanone
• CAS: 1357184-25-8
• 化学式: C₂₃H₂₅F₂N₃O₃S
• 分子量: 461.533
• InChiKey: HOZNILSWURAMGP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  87.8
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• FUSED RING PYRIDINE COMPOUND
  申请人：Astellas Pharma Inc.

  公开号：US20130143874A1

  公开（公告）日：2013-06-06

  [Problem] To provide a compound useful as a novel agent which is excellent in preventing and/or treating cannabinoid receptor type 2-related diseases, based on agonist action on a cannabinoid receptor type 2 [Means for Solution] The present inventors conducted thorough investigation regarding compounds having agonist action on a cannabinoid receptor type 2. They confirmed that the fused ring pyridine compound of the present invention has excellent agonist action on the cannabinoid receptor type 2, thereby completing the present invention. The fused ring pyridine compound of the present invention has agonist action on the cannabinoid receptor type 2, and can be used as an agent for preventing and/or treating cannabinoid receptor type 2-related diseases, for example, inflammatory diseases and pain.

  [问题] 提供一种化合物，作为一种新型药剂，具有优异的防治大麻素受体类型2相关疾病的作用，基于对大麻素受体类型2的激动剂作用[解决方案] 本发明的发明人对具有大麻素受体类型2激动剂作用的化合物进行了彻底调查。他们确认本发明的融合环吡啶化合物在大麻素受体类型2上具有优异的激动剂作用，从而完成了本发明。本发明的融合环吡啶化合物在大麻素受体类型2上具有激动剂作用，可用作预防和/或治疗大麻素受体类型2相关疾病的药剂，例如炎症性疾病和疼痛。
• US8791106B2
  申请人：——

  公开号：US8791106B2

  公开（公告）日：2014-07-29